Since the US Food and Drug Administration approval of tissue plasminogen activator (tPA) for acute stroke in 1996, stroke centers have strived to increase the proportion of eligible patients treated with tPA, to improve outcomes for patients presenting within 3 h of symptom onset (6–8). This evidence concerns the gene PLAT and Stroke.